These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 21955327)

  • 1. The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.
    Xie G; Nie T; Mackenzie GG; Sun Y; Huang L; Ouyang N; Alston N; Zhu C; Murray OT; Constantinides PP; Kopelovich L; Rigas B
    Br J Pharmacol; 2012 Apr; 165(7):2152-66. PubMed ID: 21955327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phospho-sulindac (OXT-328) combined with difluoromethylornithine prevents colon cancer in mice.
    Mackenzie GG; Ouyang N; Xie G; Vrankova K; Huang L; Sun Y; Komninou D; Kopelovich L; Rigas B
    Cancer Prev Res (Phila); 2011 Jul; 4(7):1052-60. PubMed ID: 21464038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
    Mackenzie GG; Sun Y; Huang L; Xie G; Ouyang N; Gupta RC; Johnson F; Komninou D; Kopelovich L; Rigas B
    Gastroenterology; 2010 Oct; 139(4):1320-32. PubMed ID: 20600034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ocular pharmacokinetics and biodistribution of phospho-sulindac (OXT-328) formulated in nanoparticles: Enhanced and targeted tissue drug delivery.
    Wen Z; Muratomi N; Huang W; Huang L; Ren J; Yang J; Persaud Y; Loloi J; Mallangada N; Kung P; Honkanen R; Rigas B
    Int J Pharm; 2019 Feb; 557():273-279. PubMed ID: 30597269
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phospho-sulindac (OXT-328) inhibits the growth of human lung cancer xenografts in mice: enhanced efficacy and mitochondria targeting by its formulation in solid lipid nanoparticles.
    Zhu R; Cheng KW; Mackenzie G; Huang L; Sun Y; Xie G; Vrankova K; Constantinides PP; Rigas B
    Pharm Res; 2012 Nov; 29(11):3090-101. PubMed ID: 22723123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phospho-Sulindac (OXT-328) Inhibits Dry Eye Disease in Rabbits: A Dose-, Formulation- and Structure-Dependent Effect.
    Huang W; Wen Z; Saglam MS; Huang L; Honkanen RA; Rigas B
    J Ocul Pharmacol Ther; 2021; 37(6):321-330. PubMed ID: 34152861
    [No Abstract]   [Full Text] [Related]  

  • 7. Phospho-sulindac (OXT-922) inhibits the growth of human colon cancer cell lines: a redox/polyamine-dependent effect.
    Huang L; Zhu C; Sun Y; Xie G; Mackenzie GG; Qiao G; Komninou D; Rigas B
    Carcinogenesis; 2010 Nov; 31(11):1982-90. PubMed ID: 20627873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phospho-NSAIDs have enhanced efficacy in mice lacking plasma carboxylesterase: implications for their clinical pharmacology.
    Wong CC; Cheng KW; Papayannis I; Mattheolabakis G; Huang L; Xie G; Ouyang N; Rigas B
    Pharm Res; 2015 May; 32(5):1663-75. PubMed ID: 25392229
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topically applied phospho-sulindac hydrogel is efficacious and safe in the treatment of experimental arthritis in rats.
    Mattheolabakis G; Mackenzie GG; Huang L; Ouyang N; Cheng KW; Rigas B
    Pharm Res; 2013 Jun; 30(6):1471-82. PubMed ID: 23483440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sulindac increases the expression of APC mRNA in malignant colonic epithelial cells: an in vitro study.
    Schnitzler M; Dwight T; Robinson BG
    Gut; 1996 May; 38(5):707-13. PubMed ID: 8707116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Deactivation of sulindac-sulphide by human renal microsomes.
    Eriksson LO; Boström H
    Pharmacol Toxicol; 1988 Apr; 62(4):177-83. PubMed ID: 3133648
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The in vitro metabolism of phospho-sulindac amide, a novel potential anticancer agent.
    Xie G; Cheng KW; Huang L; Rigas B
    Biochem Pharmacol; 2014 Sep; 91(2):249-55. PubMed ID: 25044307
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics.
    Cheng KW; Wong CC; Mattheolabakis G; Xie G; Huang L; Rigas B
    Int J Oncol; 2013 Sep; 43(3):895-902. PubMed ID: 23807084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination chemoprevention of intestinal carcinogenesis in a murine model of familial adenomatous polyposis.
    Ignatenko NA; Besselsen DG; Stringer DE; Blohm-Mangone KA; Cui H; Gerner EW
    Nutr Cancer; 2008; 60 Suppl 1():30-5. PubMed ID: 19003578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regioselective oxidation of phospho-NSAIDs by human cytochrome P450 and flavin monooxygenase isoforms: implications for their pharmacokinetic properties and safety.
    Xie G; Wong CC; Cheng KW; Huang L; Constantinides PP; Rigas B
    Br J Pharmacol; 2012 Sep; 167(1):222-32. PubMed ID: 22489789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Influence of K-ras activation on the survival responses of Caco-2 cells to the chemopreventive agents sulindac and difluoromethylornithine.
    Lawson KR; Ignatenko NA; Piazza GA; Cui H; Gerner EW
    Cancer Epidemiol Biomarkers Prev; 2000 Nov; 9(11):1155-62. PubMed ID: 11097222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer.
    Cheng KW; Mattheolabakis G; Wong CC; Ouyang N; Huang L; Constantinides PP; Rigas B
    Int J Oncol; 2012 Oct; 41(4):1199-203. PubMed ID: 22842609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Longitudinal assessment of air conduction audiograms in a phase III clinical trial of difluoromethylornithine and sulindac for prevention of sporadic colorectal adenomas.
    McLaren CE; Fujikawa-Brooks S; Chen WP; Gillen DL; Pelot D; Gerner EW; Meyskens FL
    Cancer Prev Res (Phila); 2008 Dec; 1(7):514-21. PubMed ID: 19139001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sulindac oxidation/reduction by microbial cultures; microbial models of mammalian metabolism.
    Davis PJ; Guenthner LE
    Xenobiotica; 1985 Oct; 15(10):845-57. PubMed ID: 4072250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Carboxylesterases 1 and 2 hydrolyze phospho-nonsteroidal anti-inflammatory drugs: relevance to their pharmacological activity.
    Wong CC; Cheng KW; Xie G; Zhou D; Zhu CH; Constantinides PP; Rigas B
    J Pharmacol Exp Ther; 2012 Feb; 340(2):422-32. PubMed ID: 22085648
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.